NRAS and acute myeloid leukemia: In the context of oncogenes and clinical characteristics, patients in the high-risk subtype were frequently accompanied by mutations of NRAS, KARS, and TP53. Of note, AML with RAS mutation was associated with VEN-resistance and monocytic phenotype (27, 81).